Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Sees Strong Trading Volume After Earnings Beat

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw strong trading volume on Tuesday following a better than expected earnings announcement. 3,152,097 shares were traded during trading, an increase of 148% from the previous session’s volume of 1,272,675 shares.The stock last traded at $11.2350 and had previously closed at $10.88.

The company reported $0.79 earnings per share for the quarter, topping analysts’ consensus estimates of $0.64 by $0.15. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS.

Analysts Set New Price Targets

A number of research firms recently weighed in on BAYRY. Zacks Research raised shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a report on Friday. DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Finally, UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research report on Monday, March 16th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Bayer Aktiengesellschaft presently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The firm’s fifty day simple moving average is $11.31 and its 200 day simple moving average is $10.91. The company has a market capitalization of $44.15 billion, a price-to-earnings ratio of -10.12 and a beta of 0.62. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.01 and a quick ratio of 0.63.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.